MET

Reference work entry
First Online:

Abstract

The receptor tyrosine kinase MET activates numerous cellular signaling pathways after binding with its ligand, hepatocyte growth factor (HGF). MET is involved in a wide range of biological processes and is critical for tissue homeostasis under physiological conditions. MET is also a known oncogene that is abnormally activated in many human cancers by mutation, protein overexpression or amplification. Furthermore, MET is implicated as a common mechanism of resistance to targeted therapies such as EGFR inhibitors. In this review, we describe the biology of MET, the mechanisms by which it becomes an oncogenic driver, its role as a target in cancer medicine, and emerging biomarkers to select patients for MET-targeted therapy. Pre-clinical and clinical data for anti-MET therapies to date are then summarized.

Keywords

Acquired TKI resistance Biomarker Cell scatter Crizotinib Gene amplification Hepatocyte growth factor (HGF) Hereditary papillary renal cell carcinoma Mesenchymal-epithelial transition (MET) receptor Oncogene Tivantinib 
This is a preview of subscription content, log in to check access.

References

  1. Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3:658–73.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007;104:20932–7.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Beau-Faller M, Ruppert AM, Voegeli AC, et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J Thorac Oncol. 2008;3:331–9.CrossRefPubMedGoogle Scholar
  4. Beilmann M, Odenthal M, Jung W, et al. Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood. 1997;90:4450–8.PubMedGoogle Scholar
  5. Benkhoucha M, Santiago-Raber ML, Schneiter G, et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25 + Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2010;107:6424–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature. 1995;376:768–71.CrossRefPubMedGoogle Scholar
  7. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006;6:637–45.CrossRefPubMedGoogle Scholar
  8. Camidge DR, Ou S-HI, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). ASCO meeting abstracts 32:8001. 2014.Google Scholar
  9. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009;27:1667–74.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31:181–6.CrossRefPubMedGoogle Scholar
  11. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003;63:7345–55.PubMedGoogle Scholar
  12. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7:504–16.CrossRefPubMedGoogle Scholar
  13. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311:29–33.CrossRefPubMedGoogle Scholar
  14. Corpechot C, Barbu V, Wendum D, et al. Hepatocyte growth factor and c-Met inhibition by hepatic cell hypoxia: a potential mechanism for liver regeneration failure in experimental cirrhosis. Am J Pathol. 2002;160:613–20.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Cunningham D, Al-Batran S-E, Davidenko I, et al. RILOMET-1: an international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. ASCO meeting abstracts 31:TPS4153. 2013.Google Scholar
  16. Davidenko I, Iveson T, Donehower R, et al. Updated efficacy, biomarker, and exposure-response data from a phase 2 study of rilotumumab (R) plus epirubicin, cisplatin, and capecitabine (ECX) in gastric or esophagogastric junction cancer. Presented at the European Society for Medical Oncology Congress, 2012.Google Scholar
  17. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res. 1995;1:147–54.PubMedGoogle Scholar
  18. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–43.CrossRefPubMedGoogle Scholar
  19. Foveau B, Ancot F, Leroy C, et al. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell. 2009;20:2495–507.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5:850–9.CrossRefPubMedGoogle Scholar
  21. Furlan A, Kherrouche Z, Montagne R, et al. Thirty years of research on met receptor to move a biomarker from bench to bedside. Cancer Res. 2014;74:6737–44.CrossRefPubMedGoogle Scholar
  22. Galimi F, Cottone E, Vigna E, et al. Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol. 2001;166:1241–7.CrossRefPubMedGoogle Scholar
  23. Galvani AP, Cristiani C, Carpinelli P, et al. Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form. Biochem Pharmacol. 1995;50:959–66.CrossRefPubMedGoogle Scholar
  24. Huff JL, Jelinek MA, Borgman CA, et al. The protooncogene c-sea encodes a transmembrane protein-tyrosine kinase related to the Met/hepatocyte growth factor/scatter factor receptor. Proc Natl Acad Sci U S A. 1993;90:6140–4.CrossRefPubMedPubMedCentralGoogle Scholar
  25. Janjigian YY, Tang LH, Coit DG, et al. MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:1021–7.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Kawaida K, Matsumoto K, Shimazu H, et al. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci U S A. 1994;91:4357–61.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Kitajima Y, Ide T, Ohtsuka T, et al. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci. 2008;99:1341–7.CrossRefPubMedGoogle Scholar
  28. Lee HE, Kim MA, Lee HS, et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 2012;107:325–33.CrossRefPubMedPubMedCentralGoogle Scholar
  29. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–10.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Liu X, Jia Y, Stoopler M, et al. Next generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. in press, 2015 Jul 27. pii: JCO.2015.62.0674. [Epub ahead of print].Google Scholar
  31. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008;47:1025–37.CrossRefPubMedPubMedCentralGoogle Scholar
  32. Maroun CR, Rowlands T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther. 2014;142:316–38.CrossRefPubMedGoogle Scholar
  33. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer. 2006;119:477–83.CrossRefPubMedGoogle Scholar
  34. Nakamura T, Mizuno S, Matsumoto K, et al. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest. 2000;106:1511–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Okunishi K, Dohi M, Nakagome K, et al. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol. 2005;175:4745–53.CrossRefPubMedGoogle Scholar
  36. Oliner KS, Tang R, Anderson A, et al Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. ASCO meeting abstracts 30:4005. 2012.Google Scholar
  37. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3:S7–19.CrossRefPubMedPubMedCentralGoogle Scholar
  38. Paik PK, Drilon A, Yu H, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5:842–9.CrossRefPubMedPubMedCentralGoogle Scholar
  39. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3:347–61.CrossRefPubMedGoogle Scholar
  40. Peschard P, Fournier TM, Lamorte L, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 2001;8:995–1004.CrossRefPubMedGoogle Scholar
  41. Ronsin C, Muscatelli F, Mattei MG, et al. A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 1993;8:1195–202.PubMedGoogle Scholar
  42. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14:55–63.CrossRefPubMedGoogle Scholar
  43. Sawada K, Radjabi AR, Shinomiya N, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007;67:1670–9.CrossRefPubMedGoogle Scholar
  44. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 1995;373:699–702.CrossRefPubMedGoogle Scholar
  45. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68–73.CrossRefPubMedGoogle Scholar
  46. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343–50.CrossRefPubMedGoogle Scholar
  47. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011a;3:75ra26.CrossRefPubMedPubMedCentralGoogle Scholar
  48. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011b;29:3307–15.CrossRefPubMedGoogle Scholar
  49. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006;103:2316–21.CrossRefPubMedPubMedCentralGoogle Scholar
  50. Sonnenberg E, Meyer D, Weidner KM, et al. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol. 1993;123:223–35.CrossRefPubMedGoogle Scholar
  51. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31:4105–14.CrossRefPubMedPubMedCentralGoogle Scholar
  52. Spigel DR, Edelman MJ, O’Byrne K, et al Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. ASCO meeting abstracts 32:8000. 2014.Google Scholar
  53. Szerlip NJ, Pedraza A, Chakravarty D, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A. 2012;109:3041–6.CrossRefPubMedPubMedCentralGoogle Scholar
  54. Takeuchi H, Bilchik A, Saha S, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res. 2003;9:1480–8.PubMedGoogle Scholar
  55. Tang Z, Du R, Jiang S, et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 2008;99:911–22.CrossRefPubMedPubMedCentralGoogle Scholar
  56. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50.Google Scholar
  57. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11:834–48.CrossRefPubMedGoogle Scholar
  58. Tsubouchi H, Niitani Y, Hirono S, et al. Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay. Hepatology. 1991;13:1–5.CrossRefPubMedGoogle Scholar
  59. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77–88.CrossRefPubMedPubMedCentralGoogle Scholar
  60. Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature. 1995;373:702–5.CrossRefPubMedGoogle Scholar
  61. van der Voort R, Taher TE, Keehnen RM, et al. Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway. J Exp Med. 1997;185:2121–31.CrossRefPubMedPubMedCentralGoogle Scholar
  62. Zeng ZS, Weiser MR, Kuntz E, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 2008;265:258–69.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Division of Hematology and OncologyColumbia University Medical CenterNew YorkUSA
  2. 2.Department of MedicineAlbert Einstein College of Medicine/Montefiore Medical CenterBronxUSA

Personalised recommendations